{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 477224887
| IUPAC_name = ''N''-[2-(5-methoxy-1''H''-indol-3-yl)ethyl]-''N''-(prop-2-en-1-yl)prop-2-en-1-amine
| image = 5-MeO-DALT.svg
| width = 200px

<!--Clinical data-->
| tradename = 
| legal_UK = Class A
| legal_status = Illegal in China, Japan, Singapore, Sweden, Florida and Louisiana

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 928822-98-4
| PubChem = 50878551
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 21106245

<!--Chemical data-->
| C=17 | H=22 | N=2 | O=1
| molecular_weight = 270.375 g/mol
| smiles = C=CCN(CCC1=CNC2=C1C=C(OC)C=C2)CC=C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H22N2O/c1-4-9-19(10-5-2)11-8-14-13-18-17-7-6-15(20-3)12-16(14)17/h4-7,12-13,18H,1-2,8-11H2,3H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = HGRHWEAUHXYNNP-UHFFFAOYSA-N
}}
'''5-MeO-DALT''' or '''''N,N''-[[IUPAC nomenclature of organic chemistry|di]] [[allyl]]-5-[[methoxy]] [[tryptamine]]''' is a [[psychedelic drug|psychedelic]] [[tryptamine]] first synthesized by [[Alexander Shulgin]].

==Chemistry==
The full name of the chemical is ''N''-[[allyl]]-''N''-[2-(5-[[methoxy]]-1H-[[indole|indol]]-3-yl)[[ethyl group|ethyl]]] [[propene|prop-2-en-1-]] [[amine]]. It is related to the compounds [[5-MeO-DPT]] and [[DALT]].

==Pharmacology==
5-MeO-DALT binds to [[5-HT1A receptor|5-HT<sub>1A</sub>]], [[5-HT1D receptor|5-HT<sub>1D</sub>]], [[5-HT1E receptor|5-HT<sub>1E</sub>]], [[5-HT2A receptor|5-HT<sub>2A</sub>]], [[5-HT2B receptor|5-HT<sub>2B</sub>]], [[5-HT2C receptor|5-HT<sub>2C</sub>]], [[5-HT6 receptor|5-HT<sub>6</sub>]], [[Alpha-2A adrenergic receptor|α<sub>2A</sub>]], [[Alpha-2B adrenergic receptor|α<sub>2B</sub>]], [[Alpha-2C adrenergic receptor|α<sub>2C</sub>]], [[Histamine H1 receptor|H<sub>1</sub>]], [[K-opioid receptor|κ-opioid]], [[Sigma-1 receptor|σ<sub>1</sub>]] and [[Sigma-2 receptor|σ<sub>2</sub>]] receptors with [[Ligand (biochemistry)|K<sub>i</sub>]] values lower than 10μM and also acts as a  [[Dopamine transporter|DAT]] and [[Serotonin transporter|SERT]] [[monoamine reuptake inhibitor]].<ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/S0960894X1530367X | title=Receptor binding profiles and quantitative structure-affinity relationships of some 5–substituted-n,n-diallyltryptamines | author=Nicholas V. Cozzi | author2=Paul F. Daley | journal=Bioorganic & Medicinal Chemistry Letters | year=December 2015 | doi=10.1016/j.bmcl.2015.12.053}}</ref>

{| class="wikitable sortable"
|'''Binding site'''
|'''pKi ± SEM at binding site'''
|-
| 5-HT<sub>1A</sub>||7.70 ± 0.10
|-
| 5-HT<sub>1B</sub>||6.13 ± 0.04
|-
| 5-HT<sub>1D</sub>||7.00 ± 0.10
|-
| 5-HT<sub>1E</sub>||6.30 ± 0.05
|-
| 5-HT<sub>2A</sub>||6.66 ± 0.08
|-
| 5-HT<sub>2B</sub>||7.23 ± 0.05
|-
| 5-HT<sub>2C</sub>||6.34 ± 0.08
|-
| 5-HT<sub>5A</sub>||5.48 ± 0.04
|-
| 5-HT<sub>6</sub>||6.81 ± 0.03
|-
| 5-HT<sub>7</sub>||7.05 ± 0.07
|-
| α<sub>2A</sub>||6.67 ± 0.07
|-
| α<sub>2B</sub>||6.14 ± 0.04
|-
| α<sub>2C</sub>||5.83 ± 0.06
|-
| H<sub>1</sub>||6.30 ± 0.06
|-
| H<sub>3</sub>||5.77 ± 0.04
|-
| κOR||5.95 ± 0.07
|-
| μOR||> 5.00
|-
| σ<sub>1</sub>||6.52 ± 0.06
|-
| σ<sub>2</sub>||6.60 ± 0.05
|-
| DAT||5.50 ± 0.20
|-
| NET||> 5.00
|-
| SERT||6.30 ± 0.05
|}

The metabolism and [[cytochrome P450]] inhibition of 5-MeO-DALT has been described in scientific literature.<ref>{{cite journal | url=https://link.springer.com/article/10.1007%2Fs00216-015-8955-0 | title=Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC–MS, LC–MS <sup>n</sup> , and LC–HR–MS–MS | author=Julian A. Michely | author2=Andreas G. Helfer | author3=Simon D. Brandt| author4=Markus R. Meyer | author5=Hans H. Maurer | journal=Analytical and Bioanalytical Chemistry |date=August 2015  | doi=10.1007/s00216-015-8955-0 | pmid=26297461 | volume=407 | pages=7831–42}}</ref><ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/S0378427415301107 | title=Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class | author=Julia Dinger | author2=Campbell Woods | author3=Simon D. Brandt| author4=Markus R. Meyer | author5=Hans H. Maurer | journal=Toxicology Letters | date=January 2016 | volume=241 | pages=82–94 | doi=10.1016/j.toxlet.2015.11.013 | pmid=26599973}}</ref>

==History==
The first material regarding the synthesis and effects of 5-MeO-DALT was sent from [[Alexander Shulgin]] to a research associate named Murple in May 2004, after which it was circulated online. In June 2004 5-MeO-DALT became available from internet [[research chemical]] vendors after being synthesized by commercial laboratories in China. In August 2004 the synthesis and effects of 5-MeO-DALT were published by [[Erowid]].<ref>{{cite web | url=https://www.vice.com/read/the-last-interview-with-alexander-shulgin-423-v17n5 | title=The Last Interview With Alexander Shulgin | publisher=Vice | date=2 May 2010 | accessdate=3 September 2015 | author=Hamilton Morris | author2=Ash Smith}}</ref>

==Dosage==
Doses ranging from 12–20&nbsp;mg were tested by Alexander Shulgin's research group.<ref>{{cite web | url=https://www.youtube.com/watch?v=ijXkk4OLDpk | title=Sasha Shulgin - 5-MeO-DALT, 2C-B-FLY & 5-EtOs | accessdate=3 September 2015}}</ref>

==Side effects==
There is no published literature on the toxicity of 5-MeO-DALT.

==Legal Status==

===China===

As of October 2015 5-MeO-DALT is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | accessdate=1 October 2015}}</ref>

===Japan===
5-MeO-DALT became a controlled substance in [[Japan]] from April 2007, by amendment to the [[Pharmaceutical Affairs Law (Japan)|Pharmaceutical Affairs Law]].<ref>{{ cite web | url = http://www.mhlw.go.jp/houdou/2007/08/h0810-3.html | title = 厚生労働省：平成１8年度無承認無許可医薬品等買上調査の結果について | language=Japanese | accessdate =24 July 2015 }}</ref>

===United Kingdom===
5-MeO-DALT became a Class A drug in the UK on January 7th 2015 after an update to the tryptamine blanket ban.

===Singapore===
5-MeO-DALT is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.<ref>{{cite web | url=http://www.cnb.gov.sg/Libraries/CNB_Newsroom_Files/CNB_NR_-_30_Apr_2015.sflb.ashx | title=CNB NEWS RELEASE | publisher=Central Narcotics Bureau (CNB) | date=30 April 2015 | accessdate=24 July 2015}}</ref>

===Sweden===
[[Riksdag|''Sveriges riksdag'']] added 5-MeO-DALT to schedule I (''"substances, plant materials and fungi which normally do not have medical use"'') as narcotics in Sweden as of May 1, 2012, published by [[Medical Products Agency (Sweden)|''Medical Products Agency'']] in their regulation '''LVFS 2012:6''' listed as '''5-MeO-DALT N-allyl-N-[2-(5-metoxi-1H-indol-3-yl)etyl]-prop-2-en-1-amin'''.<ref>{{cite web | url=https://lakemedelsverket.se/upload/lvfs/LVFS_2012_6.pdf | title=Föreskrifter om ändring i Läkemedelsverkets föreskrifter  (LVFS 2011:10) om förteckningar över narkotika | date=20 April 2012 | accessdate=3 September 2015 | language=Swedish | author=Generaldirektör Christina Rångemark Åkerman}}</ref>

===United States===
5-MeO-DALT is not scheduled at the federal level in the [[United States]],<ref name="PART 1308 — SCHEDULES OF CONTROLLED SUBSTANCES - 1308.11 Schedule I">[http://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm §1308.11 Schedule I.]</ref> but it is likely that it could be considered an analog of [[5-Meo-DiPT]] or another [[tryptamine]], in which case purchase, sale, or possession could be prosecuted under the [[Federal Analog Act]].

====Florida====
5-MeO-DALT is a Schedule I [[controlled substance]] in the state of [[Florida]] making it illegal to buy, sell, or possess in Florida.<ref name="Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL">[http://leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/0893.html Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL]</ref>

====Louisiana====
5-MeO-DALT is a Schedule I [[controlled substance]] in the state of [[Louisiana]] making it illegal to buy, sell, or possess in Louisiana.<ref>{{cite web | url=http://legis.la.gov/Legis/Law.aspx?d=98877 | title=Louisiana State Legislature | accessdate=3 September 2015}}</ref>

==Notes==
{{reflist}}

==External links==
* [https://www.erowid.org/chemicals/5meo_dalt/5meo_dalt.shtml Erowid 5-MeO-DALT vault]
* [https://www.ukchemicalresearch.org/Thread-5-MeO-DALT 5-MeO-DALT Thread at UKChemicalResearch]

{{Entactogens}}
{{Hallucinogens}}
{{Serotonin receptor modulators}}
{{Sigma receptor modulators}}
{{Tryptamines}}

[[Category:Designer drugs]]
[[Category:Entactogens and empathogens]]
[[Category:Entheogens]]
[[Category:Phenol ethers]]
[[Category:Psychedelic tryptamines]]
[[Category:Allyl compounds]]